New program will help address the growing mental health workforce crisis
The new Behavioral Health Teaching Facility at UW Medical Center – Northwest
Mountlake Terrace, Wash., Dec. 08, 2022 (GLOBE NEWSWIRE) — Premera Blue Cross today announced a $6.6 million grant to the University of Washington (UW) for the UW Psychiatry Fellowship for Advanced Nurse Practitioners (ARNPs). An innovative program in the region, the fellowship will accept up to four Psychiatric ARNP fellows each year starting in 2023. Training, to include rotations at primary care clinics and a new Behavioral Health Teaching Facility at UW Medical Center – Northwest, will focus on inpatient, outpatient, telehealth consultation and integrated psychiatric care for mental health conditions.
This investment continues Premera’s focus on addressing the growing mental health crisis. In Washington, one in five adults and one in six youth ages 6–17 experience a mental health disorder each year, according to the National Alliance on Mental Illness. However, more than half of people – both adults and adolescents – with a mental health condition did not receive any treatment in the last year.
While stigma continues to be a barrier to seeking care, provider shortages present an additional challenge. In Washington, 35 of 39 counties are federally designated as Mental Health Professional Shortage Areas with limited access to providers such as clinical psychologists, clinical social workers, psychiatric nurse specialists, and marriage and family therapists. Furthermore, nearly half the state’s counties – entirely in rural areas – do not have a single psychiatrist offering direct patient care.
“If we want to see improvements to healthcare in the future, we need to invest in sustainable solutions now,” said Jeffrey Roe, President and CEO of Premera Blue Cross. “The University of Washington continues to find innovative ways to provide better access to mental healthcare. Developing a strong workforce means communities will benefit for years to come.”
The training provided by this fellowship will allow psychiatric mental health nurse practitioners to further develop their expertise and serve in a variety of roles in Washington. This includes serving as a psychiatric consult through the Collaborative Care Model, leveraging their expertise in partnership with primary care teams for patients in both urban and rural settings. Developed at UW Medicine to treat common and persistent mental health conditions such as depression and anxiety, the Collaborative Care Model integrates mental health services into primary care clinics with regular psychiatric case consultation for patients who are not improving as expected.
“Our future fellows will transform the access to effective mental health care across Washington state through collaboration, community support, and sustainable access to evidence-based care for patient and families,” said Dr. Anna Ratzliff, professor, Psychiatry, University of Washington School of Medicine.
“This fellowship will prepare a new pipeline of psychiatric mental health nurse practitioners for leadership roles in complex clinical care environments, mentoring other nurses and interprofessional mental health providers, and improving equitable access to mental health care, said Azita Emami, Executive Dean of the UW School of Nursing. “This program, developed in collaboration between the University of Washington Schools of Nursing and Medicine and the UW Medical Center, will serve as a precedent for expanding collaborative education and training efforts to other specialty areas,” said Tatiana Sadak, Interim Associate Dean for Academic Affairs at the UW School of Nursing.
This investment builds on Premera and the UW’s goal to improve health outcomes across Washington, including:
Premera’s $10 million investment in 2019 in the UW School of Medicine to support the integration of the Collaborative Care model into primary care clinics across rural areas. To date, 23 clinics have implemented the Collaborative Care model through this grant.
A $4.7 million grant from Premera in 2020 to the UW School of Nursing, which established the Rural Nursing Health Initiative. This program has placed nearly 40 ARNP students in rural practices in Washington.
This joint advanced clinical training program also represents a first-of-its-kind partnership between the UW School of Medicine and the UW School of Nursing — two top tier schools at the University of Washington. The UW School of Nursing is the nation’s No. 1 public nursing school with a Doctor of Nursing Practice program, while the UW School of Medicine has the nation’s No. 1 primary care education and training program, according to U.S. News and World Report. The UW School of Medicine also has the largest psychiatry residency program in the country with more than 90 residents being trained at any given time. Serving as the training ground for the ARNP fellows, it is the only academic psychiatry department serving the Washington, Wyoming, Alaska, Montana, and Idaho region.
These investments are part of Premera’s larger strategy to improve access to care in rural areas, specifically focused on physician, nurse and health aide recruitment and training; clinical integration of behavioral health; programs to increase the capacity of mental health crisis centers in rural areas; and small equipment grants to rural providers.
About Premera Blue Cross
Premera Blue Cross, a not-for-profit, independent licensee of the Blue Cross Blue Shield Association based in Mountlake Terrace, Wash., is a leading health plan in the Pacific Northwest, providing comprehensive health benefits and tailored services to more than 2.75 million people, from individuals to Fortune 100 companies.
About the UW School of Nursing
The University of Washington School of Nursing is consistently a top-ranked nursing school, with the #1 ranking among public schools of nursing with a DNP program, according to U.S. News & World Report. The UW School of Nursing is a national and international leader in improving the health and well-being of individuals, families and communities. The school addresses society’s most pressing challenges in health care through innovative teaching, award winning research and community service. For more information, visit www.nursing.uw.edu.
About the UW School of Medicine
The UW School of Medicine serves a five-state region: Washington, Wyoming, Alaska, Montana and Idaho (WWAMI). U.S. News & World Report currently ranks the UW School of Medicine as best in the nation for primary care education and training and second in the nation for NIH research grants with $1.3 billion in fiscal year 2020. There are approximately 4,800 students and trainees in the School of Medicine.
Attachment
The new Behavioral Health Teaching Facility at UW Medical Center – Northwest
RYU Apparel Inc. (TSXV: RYU); (OTCQB: RYPPF); (FWB: RYA) ("RYU" or the "Company"), announces that further to its news release dated December 1, 2022, it has received acceptance from the TSX Venture Exchange (the "TSXV") to extend the expiry date of 13,709,612 common share purchase warrants (the "Warrants"), issued by the Company in connection with a private placement financing that closed on December 22, 2020, from December 22, 2022 to December 22, 2025. In all other respects, the terms of the W
Shares of BioVie (NASDAQ: BIVI) were soaring 23.6% higher as of 11:19 a.m. ET on Thursday. The big jump appears to be the result of a delayed positive reaction by investors after the drugmaker reported results earlier this week from a phase 2 study evaluating experimental therapy NE3107. On Tuesday, BioVie's share price tumbled after the company's Monday evening announcement of results from its phase 2 study of NE3107 in treating Alzheimer's disease and Parkinson's disease.
Mirati Therapeutics' pain continued Thursday amid a series of analyst downgrades after MRTX stock lost about half of its value in three days.
Eli Lilly (NYSE: LLY), CRISPR Therapeutics (NASDAQ: CRSP), and Johnson & Johnson (NYSE: JNJ) have all been doing so. Eli Lilly and CRISPR are developing radical new therapies, while Johnson & Johnson is going all-in on using artificial intelligence to bring new therapies to market more quickly. It's hard to see Eli Lilly as a revolutionary stock.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Veru Inc. (NASDAQ:VERU) Q4 2022 Earnings Call Transcript December 5, 2022 Veru Inc. misses on earnings expectations. Reported EPS is $-0.51 EPS, expectations were $-0.3. Operator: Good morning ladies and gentlemen, and welcome to Veru Inc.’s Investor Conference Call. All participants will be in listen-only mode. After this morning’s discussion, there will be an opportunity […]
Shares of Relmada Therapeutics Inc. tumbled about 40% in premarket trading on Thursday, the day after the company said its experimental depression drug did not meet the primary endpoint in a Phase 3 clinical trial. The stock closed Wednesday at $4.16, a three-year low. The study was evaluating REL-1017 as an adjunctive treatment for major depressive disorder. The same drug previously failed as a monotherapy for the same condition. Relmada said it is continuing to study the investigational therap
Is Pfizer stock a buy after the FDA gives it a speedy review for an older adult RSV vaccine? Is PFE stock a buy right now?
Esperion Therapeutics Inc's (NASDAQ: ESPR) CLEAR Outcomes trial met its primary endpoint, demonstrating statistically significant risk reduction in MACE-4 in patients treated with 180 mg/day NEXLETOL (bempedoic acid) compared to placebo. The data demonstrate statistically significant and clinically meaningful results. The study included over 14,000 patients at over 1,200 sites in 32 countries. Bempedoic acid becomes the first ATP citrate lyase inhibitor and oral non-statin to meet the major adve
The FDA's decision on Pfizer's (PFE) BLA seeking approval for RSV vaccine candidate in older adults is expected in May 2023.
Prometheus Bio reported promising results from two inflammatory disease studies on Wednesday, and RXDX stock catapulted higher.
A U.S. district court dismisses thousands of lawsuits involving Zantac. Relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE).
Led by a veteran of BridgeBio, the virtual company isn't saying much about the targets of its drugs, which were spun over to it by Paragon Therapeutics.
The fight between the teacher and student happened in the middle school classroom
Gilead faces some challenges. But there are several reasons to think the stock could keep the momentum going.
Masimo's (MASI) full-market release of the Hi for the Masimo W1 watch is likely to significantly improve RPM.
Peanut butter can help you build muscle, lose weight, and improve your health—but you have to know which kind to buy. Dietitians explain.
GSK plc (NYSE: GSK) announced results from the PERLA phase 2 trial investigating Jemperli (dostarlimab) + chemotherapy versus Merck & Co Inc's (NYSE: MRK) Keytruda pembrolizumab + chemo as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). Dostarlimab plus chemotherapy achieved promising results for the primary endpoint of confirmed objective response rate (ORR) and the key secondary endpoint of median progression-free survival (mPFS). The ORR was 46% (n=56/12
Novartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naive (including anti-C5 therapies) adults with PNH meets its primary endpoint.
China has acknowledged low vaccinations rates for the elderly and is seeking to boost them.